デング熱ワクチンの世界市場2021年-2025年

◆英語タイトル:Global Dengue Vaccine Market 2021-2025
◆商品コード:IRTNTR44127
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年5月18日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、アジア、ヨーロッパ、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社は、デング熱ワクチンの世界市場規模が2021年から2025年まで年平均約18%成長し、132.90百万ドルに達すると予測しています。本調査資料では世界のデング熱ワクチン市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、エンドユーザー別(政府機関、病院、NGO)分析、顧客状況、地域別状況、企業状況、企業分析など、以下の項目を掲載しています。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・デング熱ワクチンの世界市場規模:エンドユーザー別(政府機関、病院、NGO)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Dengue Vaccine Market 2021-2025

Technavio has been monitoring the dengue vaccine market and it is poised to grow by $ 132.90 million during 2021-2025, progressing at a CAGR of about 18% during the forecast period. Our report on the dengue vaccine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rapid growth in disease prevalence and ineffective dengue control measures. In addition, rapid growth in disease prevalence is anticipated to boost the growth of the market as well.

The dengue vaccine market analysis includes the end-user segment and geographic landscape.
Technavio’s dengue vaccine market is segmented as below:

By End-user
• Government institutions
• Hospitals
• NGOs

By Geographical Landscape
• North America
• Asia
• Europe
• ROW

This study identifies the initiatives for dengue vaccine research and dengue immunization programs as one of the prime reasons driving the dengue vaccine market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on dengue vaccine market covers the following areas:
• Dengue vaccine market sizing
• Dengue vaccine market forecast
• Dengue vaccine market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading dengue vaccine market vendors that include BioNet-Asia Co. Ltd., Chula VRC, Codagenix Inc., GeneOne Life Science Inc., Imutex Ltd., KM Biologics Co. Ltd., Medigen Biotechnology Corp., Najít Technologies Inc., Sanofi SA, and Emergex Vaccines Holding Ltd. Also, the dengue vaccine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/dengue-vaccine-market-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

【レポートの目次】

• Executive Summary
o Market overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five Forces Analysis
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by End-user
o Market segments
o Comparison by End-user
o Government institutions – Market size and forecast 2020-2025
o Hospitals – Market size and forecast 2020-2025
o NGOs – Market size and forecast 2020-2025
o Market opportunity by End-user
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Competitive Scenario
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o BioNet-Asia Co. Ltd.
o Chula VRC
o Codagenix Inc.
o Emergex Vaccines Holding Ltd.
o GeneOne Life Science Inc.
o Imutex Ltd.
o KM Biologics Co. Ltd.
o Medigen Biotechnology Corp.
o Najít Technologies Inc.
o Sanofi SA
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: End user – Market share 2020-2025 (%)
• 22: Comparison by End user
• 23: Government institutions – Market size and forecast 2020-2025 ($ million)
• 24: Government institutions – Year-over-year growth 2020-2025 (%)
• 25: Hospitals – Market size and forecast 2020-2025 ($ million)
• 26: Hospitals – Year-over-year growth 2020-2025 (%)
• 27: NGOs – Market size and forecast 2020-2025 ($ million)
• 28: NGOs – Year-over-year growth 2020-2025 (%)
• 29: Market opportunity by End user
• 30: Customer landscape
• 31: Market share by geography 2020-2025 (%)
• 32: Geographic comparison
• 33: North America – Market size and forecast 2020-2025 ($ million)
• 34: North America – Year-over-year growth 2020-2025 (%)
• 35: Asia – Market size and forecast 2020-2025 ($ million)
• 36: Asia – Year-over-year growth 2020-2025 (%)
• 37: Europe – Market size and forecast 2020-2025 ($ million)
• 38: Europe – Year-over-year growth 2020-2025 (%)
• 39: ROW – Market size and forecast 2020-2025 ($ million)
• 40: ROW – Year-over-year growth 2020-2025 (%)
• 41: Key leading countries
• 42: Market opportunity by geography ($ million)
• 43: Impact of drivers and challenges
• 44: Vendor landscape
• 45: Landscape disruption
• 46: Industry risks
• 47: Vendors covered
• 48: Market positioning of vendors
• 49: BioNet-Asia Co. Ltd. – Overview
• 50: BioNet-Asia Co. Ltd. – Product and service
• 51: BioNet-Asia Co. Ltd. – Key offerings
• 52: BioNet-Asia Co. Ltd. – Key customers
• 53: BioNet-Asia Co. Ltd. – Segment focus
• 54: Chula VRC – Overview
• 55: Chula VRC – Product and service
• 56: Chula VRC – Key offerings
• 57: Chula VRC – Key customers
• 58: Chula VRC – Segment focus
• 59: Codagenix Inc. – Overview
• 60: Codagenix Inc. – Product and service
• 61: Codagenix Inc. – Key offerings
• 62: Codagenix Inc. – Key customers
• 63: Codagenix Inc. – Segment focus
• 64: Emergex Vaccines Holding Ltd. – Overview
• 65: Emergex Vaccines Holding Ltd. – Product and service
• 66: Emergex Vaccines Holding Ltd. – Key offerings
• 67: Emergex Vaccines Holding Ltd. – Key customers
• 68: Emergex Vaccines Holding Ltd. – Segment focus
• 69: GeneOne Life Science Inc. – Overview
• 70: GeneOne Life Science Inc. – Product and service
• 71: GeneOne Life Science Inc. – Key offerings
• 72: GeneOne Life Science Inc. – Key customers
• 73: GeneOne Life Science Inc. – Segment focus
• 74: Imutex Ltd. – Overview
• 75: Imutex Ltd. – Product and service
• 76: Imutex Ltd. – Key offerings
• 77: Imutex Ltd. – Key customers
• 78: Imutex Ltd. – Segment focus
• 79: KM Biologics Co. Ltd. – Overview
• 80: KM Biologics Co. Ltd. – Product and service
• 81: KM Biologics Co. Ltd. – Key offerings
• 82: KM Biologics Co. Ltd. – Key customers
• 83: KM Biologics Co. Ltd. – Segment focus
• 84: Medigen Biotechnology Corp. – Overview
• 85: Medigen Biotechnology Corp. – Product and service
• 86: Medigen Biotechnology Corp. – Key offerings
• 87: Medigen Biotechnology Corp. – Key customers
• 88: Medigen Biotechnology Corp. – Segment focus
• 89: Najít Technologies Inc. – Overview
• 90: Najít Technologies Inc. – Product and service
• 91: Najít Technologies Inc. – Key offerings
• 92: Najít Technologies Inc. – Key customers
• 93: Najít Technologies Inc. – Segment focus
• 94: Sanofi SA – Overview
• 95: Sanofi SA – Business segments
• 96: Sanofi SA – Key offerings
• 97: Sanofi SA – Key customers
• 98: Sanofi SA – Segment focus
• 99: Currency conversion rates for US$
• 100: Research Methodology
• 101: Validation techniques employed for market sizing
• 102: Information sources
• 103: List of abbreviations



【掲載企業】

BioNet-Asia Co. Ltd., Chula VRC, Codagenix Inc., GeneOne Life Science Inc., Imutex Ltd., KM Biologics Co. Ltd., Medigen Biotechnology Corp., Najít Technologies Inc., Sanofi SA, Emergex Vaccines Holding Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[デング熱ワクチンの世界市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆